AstraZeneca Appeals Toprol-XL Patent Invalidity

Law360, New York (February 16, 2006, 12:00 AM EST) -- Pharmaceutical company AstraZeneca PLC is appealing a federal court ruling that scuttled its patents for the valuable heart drug Toprol-XL and threatened its pipeline of branded drugs.

AstraZeneca, the third largest drug maker in Europe, had sued Florida-based generic drug company Andrx Corp. over its attempts to manufacture and market the drug prior its September 2007 loss of patent protection.

The January decision from the U.S. District Court for the Eastern District of Missouri, declared the patents to be invalid and unenforceable because they constitute double-patenting....
To view the full article, register now.